Lewis K, Maio M, Demidov L, et al. BRIM8: a randomized, double-blind, placebo-controlled study of adjuvant vemurafenib in patients (pts) with completely resected, BRAFV600+ melanoma. ESMO 2017, abstract LBA7_PR.
Associaties tussen eerste primaire tumor en risico op volgende primaire tumor
jan 2021 | Gynaecologische oncologie, Hoofd-halsoncologie, Longoncologie, Maag-darm-leveroncologie